AbbVie Inc (NYSE:ABBV)

During the Trading Day
59.62 -0.84 / -1.39%
As of 4:02pm ET
Day’s Change
During After-Hours   Switch to standard view »
59.50 -0.12 / -0.20%
 
Volume: 257.1K
Dynavax Technologies: A New 'Best Idea'
10:33am / TheStreet.com
$20 Billion Market: Whatbs the Best Stock to Buy?
Feb 20 / MotleyFool.com
These Stocks Just Raised Their Dividends
Mar 02 / MotleyFool.com
Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Feb 19 / MotleyFool.com
Billionaire George Soros Just Dumped These 3 Dividend Stocks
Mar 01 / MotleyFool.com
Is Gilead Sciences Inc. Stock Cheap Now?
Feb 18 / MotleyFool.com
Biotech Head-to-Head: Gilead vs. Celgene
Feb 26 / MotleyFool.com
Monday interview: Flemming Ornskov, Shire CEO
Feb 15 / FT.com
Cyberonics, Sorin Plan to Merge in Latest Tax Inversion Deal
Feb 26 / TheStreet.com
Two's a duopoly, three's awkward for Kirstie, Phil and Zoopla
Feb 12 / FT.com
Heavy News Day For Several Biotech Stocks
Feb 25 / Benzinga
Shire says $1.6bn windfall from AbbVie is tax-free
Feb 12 / FT.com
Express Scripts Earnings Set the Stage for Growth
Feb 24 / MotleyFool.com
Healthcare: The race to cure rising drug costs
Feb 10 / FT.com
There Are Crazy Valuations, and Then There Are the Valuations of These 3 Stocks
Feb 22 / MotleyFool.com
Gilead to cut price of $1,000-a-day pill
Feb 03 / FT.com
3 Biotech Stocks I'd Love to Stash Away in My Portfolio Forever
Feb 22 / MotleyFool.com
Big pharmaceuticals groups faces biosimilars challenge
Feb 02 / FT.com
Pssst... Pfizer Just Told Investors That This is the Next Big Thing
Feb 21 / MotleyFool.com
Shire gets go-ahead to market binge-eating medicine
Feb 01 / FT.com
Will Express Scripts (ESRX) Beat Q4 Earnings Estimates? - Analyst Blog
Feb 20 / Zacks.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account